Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722917 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 323
- Enrollment target
NCT00722917 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 323 participants.
The verdict
NCT00722917, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 323 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of multiple doses of TAK-379, once daily (QD), in subjects with type 2 diabetes mellitus.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG TAK-379
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722917
The ClinicalTrials.gov registry entry for NCT00722917 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00722917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00722917 about?
NCT00722917 is a clinical study titled "Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the safety and effectiveness of multiple doses of TAK-379, once daily (QD), in subjects with type 2 diabetes mellitus.
What is the current status of trial NCT00722917?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 323 participants. The study started on 2008-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00722917?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), TAK-379 (DRUG).
Who is sponsoring clinical trial NCT00722917?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.